282 related articles for article (PubMed ID: 37039902)
1. A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival.
Ding J; Ji X; Liu L; Chen DZ; Luo N; Yu XT; Guo F
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7857-7876. PubMed ID: 37039902
[TBL] [Abstract][Full Text] [Related]
2. A Pan-Cancer Analysis Revealing the Dual Roles of Lysine (K)-Specific Demethylase 6B in Tumorigenesis and Immunity.
Ding JT; Yu XT; He JH; Chen DZ; Guo F
Front Genet; 2022; 13():912003. PubMed ID: 35783266
[No Abstract] [Full Text] [Related]
3. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
[TBL] [Abstract][Full Text] [Related]
4. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
5. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
6. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of Glutamate-Rich WD Repeat-Containing Protein 1 and Its Potential Clinical Significance for Pancancer.
Wu Y; Wu X; Li Y; Zhao W; Yue Y; Wu B; Liu J; Chen X; Shen A
Biomed Res Int; 2021; 2021():8201377. PubMed ID: 34616846
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy.
Jia Y; Guo B; Zhang W; Wang F; Zhang Y; Zhang Q; Li E
Front Oncol; 2023; 13():1110207. PubMed ID: 37427102
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
10. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
[No Abstract] [Full Text] [Related]
11. RecQ mediated genome instability 2 (
Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
13. Pan-Cancer Study of SHC-Adaptor Protein 1 (SHC1) as a Diagnostic, Prognostic and Immunological Biomarker in Human Cancer.
Chen J; Gao G; Li L; Ding J; Chen X; Lei J; Long H; Wu L; Long X; He L; Shen Y; Yang J; Lu Y; Sun Y
Front Genet; 2022; 13():817118. PubMed ID: 35601500
[No Abstract] [Full Text] [Related]
14. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5.
Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW
Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205
[TBL] [Abstract][Full Text] [Related]
15. Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets.
Jiang F; Shi Y; Wang Y; Ge C; Zhu J; Fang H; Zhang Y; Zhang Y; Jian H; Lei T; Lan S; Cao L; Yu H; Fang D
Aging (Albany NY); 2023 Mar; 15(6):2066-2081. PubMed ID: 36920183
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of
Liu J; Zhu B; Chen J; Cao Y
Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
[TBL] [Abstract][Full Text] [Related]
17. FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration.
Cai J; Ye Z; Hu Y; Wang Y; Ye L; Gao L; Sun Q; Tong S; Sun Z; Yang J; Chen Q
Front Oncol; 2022; 12():998336. PubMed ID: 36185230
[TBL] [Abstract][Full Text] [Related]
18. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
19. PRKCSH serves as a potential immunological and prognostic biomarker in pan-cancer.
Wang Q; Wang X; Li J; Yin T; Wang Y; Cheng L
Sci Rep; 2024 Jan; 14(1):1778. PubMed ID: 38245572
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
